Free Newsletter
AZ cancer drug gets extended exclusivity
Free newsletter via e-mail
Tools
AstraZeneca got a bit of a windfall today from the FDA, which granted six extra months of exclusive marketing rights to its Arimidex cancer drug. The drug's patent was set to expire in December 2009.
Currently, Arimidex is approved as a first-line and add-on breast-cancer treatment. The drug brought in $507 million during the first nine months of this year. AZ had been studying Arimidex for use in children whose estrogen production is abnormally high, but the trial results weren't favorable enough for the company to seek a new indication.
- see the release from AstraZeneca
Related Articles:
Arimidex wins new indication. Report
Analyst: AZ "worst performer" in pharma
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: